Cogent Biosciences, Inc. Deferred Revenue
Cogent Biosciences, Inc. (COGT) had Deferred Revenue of $17.95 million as of 2018-12-31, per its 10-K filed 2019-03-28.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2019-03-28
- 2018-12-31: Deferred Revenue, Current $17.95M.
- 2018-09-30: Deferred Revenue, Current $20.09M.
- 2018-06-30: Deferred Revenue, Current $20.36M.
- 2018-03-31: Deferred Revenue, Current $17.52M.
| Period end | Deferred Revenue, Current |
|---|---|
| 2018-12-31 | $17.95M 10-K · filed 2019-03-28 |
| 2018-09-30 | $20.09M 10-Q · filed 2018-11-13 |
| 2018-06-30 | $20.36M 10-Q · filed 2018-08-13 |
| 2018-03-31 | $17.52M 10-Q · filed 2018-05-14 |
| 2017-12-31 | $6.89M 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |